Clinical trials Brief October 16, 2026, 10:02 AM ET

Eli Lilly posts results of Phase 3 orforglipron vs dapagliflozin study

The company posted results for the ACHIEVE-2 study, a Phase 3, randomized, open-label trial that enrolled 962 participants with type 2 diabetes. The study compared once-daily oral orforglipron (LY3502970) with dapagliflozin and completed primary data collection on September 26, 2025.

Primary source

ClinicalTrials.gov results record, October 16, 2026

A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin

Read the source: A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin clinicaltrials.gov

By The Priority Review desk. Machine-summarized from the source above; not independently reported. How we use automation